<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306656</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF1797</org_study_id>
    <secondary_id>R01DK084986-05</secondary_id>
    <nct_id>NCT01306656</nct_id>
  </id_info>
  <brief_title>Vitamin D Repletion in Primary Hyperparathyroidism</brief_title>
  <official_title>Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the effect of 2 treatment regimens that contain vitamin D in a
      six-month treatment trial of patients with PHPT who are vitamin D deficient. Patients will be
      assigned randomly to one of 2 regimens, and will be followed with tests of their blood, urine
      and bones. This study should provide important information on the effect of vitamin D therapy
      in patients with PHPT. In addition, data from this study will guide physicians as to how best
      to treat their patients who have PHPT and vitamin D deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hyperparathyroidism (PHPT) is a common disease in which the parathyroid glands
      produce excessive amounts of parathyroid hormone (PTH), which regulates calcium levels. In
      primary hyperparathyroidism, high levels of PTH remove too much calcium from bones and
      deposit the excess calcium in the blood, which is then filtered into the urine by the
      kidneys. Bone health is threatened by the excess calcium loss which weakens the structure of
      the bones.

      Many patients with primary hyperparathyroidism also have low vitamin D (25OHD) levels which
      is thought to further impair bone health. Recent medical guidelines recommend treating
      patients with primary hyperparathyroidism who have low vitamin D levels with oral vitamin D
      but the optimal vitamin D dose and rate of repletion is unclear. It is, therefore, important
      to determine if replenishing Vitamin D will improve bone health in primary
      hyperparathyroidism, and if so, to assess the impact of the rate of vitamin D repletion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Active arm:
Month 1: 20,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.
Months 2-6: 10,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.
Placebo arm:
Month 1: Placebo once a week plus daily multivitamin with 400 IU vitamin D.
Months 2-6: Placebo every week plus daily multivitamin with 400 IU vitamin D.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient, investigator and study team will be blinded to study arm ramdomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum parathyroid hormone (PTH) level</measure>
    <time_frame>6 months</time_frame>
    <description>This is designed to measure how many participants will achieve PTH &gt; 65 pg/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of the lumbar spine</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by dual-energy x-ray absorptiometry (DEXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone density at the forearm</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by high resolution peripheral quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary calcium level</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>This is designed to measure how the study treatment will affect urinary calcium level over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus a multivitamin with 400 IU vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10,000 IU Vitamin D3</intervention_name>
    <description>Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Cholecalciferol-D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Month 1: Placebo once a week
Months 2-6: Placebo once a week</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Placebo pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Daily multivitamin with 400 IU vitamin D.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed PHPT, defined by an elevated serum calcium level (we will not study
             normocalcemic PHPT) with elevated or inappropriately normal PTH levels.

          -  Vitamin D3 less than 30 ng/ml

        Exclusion Criteria:

          -  Patients with familial hyperparathyroid syndromes

          -  Current or past use of the following medications: bisphosphonate within past 2 years,
             use of lithium or thiazide diuretics, current use of cinacalcet, use of aluminum
             containing medications, cimetidine, colestipol, or orlistat

          -  Malignancy, except cured basal or squamous cell skin carcinoma or other cured cancers
             that are at least five years free from recurrence

          -  History or current diagnosis of certain medical diseases (including sarcoidosis,
             active infectious granulomatous disease, HIV/AIDS, chronic kidney disease (serum
             creatinine &gt; 1.5 mg/dL), liver disease; GI diseases known to affect calcium
             metabolism; secondary hyperparathyroidism);

          -  We will also exclude patients with calcium above 11.5 mg/dL, urine calcium above 350
             mg/day, and active nephrolithiasis because vitamin D repletion could potentially
             exacerbate hypercalcemia or hypercalciuria

          -  Other exclusions include protected individuals (institutionalized), prisoners, and any
             other prospective participant who might not be able to give voluntary informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shonni J Silverberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <disposition_first_submitted>March 5, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 19, 2018</disposition_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endocrinology</keyword>
  <keyword>Metabolic Bone Disease</keyword>
  <keyword>Primary Hyperparathyroidism</keyword>
  <keyword>PHPT</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Hyper-calcemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

